Back to Search
Start Over
Preclinical toxicity and pharmacokinetics of a new orally bioavailable flubendazole formulation and the impact for clinical trials and risk/benefit to patients
- Source :
- PLoS Neglected Tropical Diseases, Vol 13, Iss 1, p e0007026 (2019), PLoS Neglected Tropical Diseases
- Publication Year :
- 2019
- Publisher :
- Public Library of Science (PLoS), 2019.
-
Abstract
- Background Flubendazole, originally developed to treat infections with intestinal nematodes, has been shown to be efficacious in animal models of filarial infections. For treatment of filarial nematodes, systemic exposure is needed. For this purpose, an orally bioavailable amorphous solid dispersion (ASD) formulation of flubendazole was developed. As this formulation results in improved systemic absorption, the pharmacokinetic and toxicological profile of the flubendazole ASD formulation have been assessed to ensure human safety before clinical trials could be initiated. Methods & findings Safety pharmacology, toxicity and genotoxicity studies have been conducted with the flubendazole ASD formulation. In animals, flubendazole has good oral bioavailability from an ASD formulation ranging from 15% in dogs, 27% in rats to more than 100% in jirds. In in vivo toxicity studies with the ASD formulation, high systemic exposure to flubendazole and its main metabolites was reached. Flubendazole, up to high peak plasma concentrations, does not induce Cmax related effects in CNS or cardiovascular system. In repeated dose toxicity studies in rats and dogs, flubendazole-induced changes were observed in haematological, lymphoid and gastrointestinal systems and in testes. In dogs, the liver was an additional target organ. Upon treatment cessation, at least partial recovery was observed for these changes in dogs. In rats, the No Observed Adverse Effect Level (NOAEL) was 5 mg (as base)/kg body weight/day (mg eq./kg/day) in males and 2.5 mg eq./kg/day in females. In dogs, the NOAEL was lower than 20 mg eq./kg/day. Regarding genotoxicity, flubendazole was negative in the Ames test, but positive in the in vivo micronucleus test. Conclusions Based on these results, in combination with previously described genotoxicity and reproductive toxicity data and the outcome of the preclinical efficacy studies, it was concluded that no flubendazole treatment regimen can be selected that would provide efficacy in humans at safe exposure.<br />Author summary This article describes pharmacokinetic profiles and results of safety pharmacology, toxicity and genotoxicity studies with an oral ASD formulation of flubendazole with improved bioavailability. Flubendazole administered as ASD formulation has good oral bioavailability in animals ranging from 15% to more than 100%. In in vivo toxicology studies, increased systemic exposure does not induce Cmax-related effects in CNS and cardiovascular systems. Increased exposure upon repeated dosing results in changes in haematological, lymphoid and gastrointestinal systems and in testes. In dogs, the liver was an additional target organ. These changes were at least partially reversible. Flubendazole is negative in the Ames test but positive in the in vivo micronucleus test. Because of the carcinogenic risk associated with this positive effect in the in vivo micronucleus test, exposure duration in patients should not exceed one day. Flubendazole-induced toxicity and associated risk is monitorable and controllable in patients if stringent precautions are applied in view of testicular toxicity and previously described teratogenicity. Considering both, treatment regimen needed for efficacy and outcome of toxicity and genotoxicity studies, it was concluded that the risk/benefit associated with the use of orally bioavailable flubendazole for the treatment of onchocerciasis in the field does not support further development.
- Subjects :
- Male
0301 basic medicine
Physiology
RC955-962
Drug Evaluation, Preclinical
Administration, Oral
Flubendazole
Protozoology
Micronuclei
Pharmacology
Toxicology
Pathology and Laboratory Medicine
Biochemistry
Rats, Sprague-Dawley
chemistry.chemical_compound
0302 clinical medicine
Animal Cells
Oral administration
Red Blood Cells
Arctic medicine. Tropical medicine
Medicine and Health Sciences
Metabolites
Medicine
Oral Administration
Routes of Administration
Mammals
Antinematodal Agents
Eukaryota
Body Fluids
Mebendazole
Blood
Infectious Diseases
Vertebrates
Toxicity
Female
Anatomy
Cellular Types
Public aspects of medicine
RA1-1270
Reproductive toxicity
Research Article
No-observed-adverse-effect level
030231 tropical medicine
Cmax
Microbiology
Blood Plasma
03 medical and health sciences
Dogs
Signs and Symptoms
Pharmacokinetics
Diagnostic Medicine
Animals
Blood Cells
Mutagenicity Tests
business.industry
Organisms
Public Health, Environmental and Occupational Health
Biology and Life Sciences
Cell Biology
Bioavailability
Metabolism
030104 developmental biology
chemistry
Amniotes
Atrophy
Gerbillinae
business
Subjects
Details
- ISSN :
- 19352735
- Volume :
- 13
- Database :
- OpenAIRE
- Journal :
- PLOS Neglected Tropical Diseases
- Accession number :
- edsair.doi.dedup.....9ca316b2ae83540612abb06d551d1780